Tandem Diabetes receives CE mark approval for Tandem Mobi with Control-IQ+; EU launch planned by end 2025

TANDEM DIABETES CARE INC

CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.
Company will pursue in-country registrations and reimbursement in EU markets.
EU commercial launches targeted to begin by end of 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.